Pfizer/Neurocrine Indiplon NDA Expected Mid-Year; Long-Term Data Reported

The companies’ upcoming submissions will cover immediate- and modified-release formulations. Two pivotal three-month studies of indiplon show highly statistically significant results for sleep onset and total sleep time.